Eli Lilly Stock: Is It Still a Buy at $1,400?

Eli Lilly reported third-quarter revenue of $24.4 billion, up 39% year over year, and raised full-year sales guidance to $91–$92 billion from $85–$87 billion, while trimming EPS guidance by $0.50 at both ends to $35–$36. Mounjaro and Zepbound generated a combined $16.1 billion, roughly two-thirds of sales. Despite strong growth, the article warns that the stock’s 45-times trailing earnings valuation and 46% six-month gain may leave limited room for error or near-term upside.

Analysis

The key signal is the disconnect between stronger sales expectations and lower EPS guidance: incremental demand is not automatically translating into incremental earnings. Before underwriting the higher revenue trajectory, verify management’s EPS bridge, including pricing, product mix, manufacturing investment, and launch costs. If the conversion gap persists, consensus earnings estimates—not sales—are the likely pressure point for a premium-multiple stock.

Near term, after a sharp rerating, the asymmetry is unfavorable for fresh outright longs: even continued growth may not support further multiple expansion, while a modest miss on prescriptions, access, or margins could compress the multiple. Over 1–3 months, track prescription trends, payer coverage, supply availability, and the next guidance update; competition from Novo Nordisk and additional entrants could constrain realized pricing or share even as category demand expands. Over 6–18 months, manufacturing capacity and broader access could enlarge the market, but also require investment and expose the franchise to reimbursement and substitution risk.

Contrarian point: concentration in GLP-1s is not solely a vulnerability; it gives Lilly substantial operating leverage if demand and access broaden. The market may be overpricing near-term perfection while underweighting a durable category expansion. That supports avoiding an unhedged short, but does not remove valuation risk. No evidence here establishes why EPS guidance fell, so the margin thesis remains conditional.

Key Decisions for Investors

• Do not chase LLY after the rerating; for existing exposure, consider trimming into strength or using a defined-risk put spread as an event hedge rather than establishing an outright short. Entry is most attractive after a further rally or ahead of a catalyst only if option pricing is reasonable; the main risk is continued earnings beats driving further upside.
• Make the next guidance update the test: require a clear reconciliation of revenue growth to EPS and monitor realized pricing, product mix, and manufacturing costs. Persistent sales/EPS divergence or a downward consensus earnings revision falsifies the bull case; improving conversion supports holding through volatility.
• Track prescription and payer-access data alongside supply and competitive updates from Novo Nordisk and other entrants. A sustained share or access deterioration is a reason to reduce exposure; category growth without Lilly-specific share evidence is not sufficient to assume continued dominance.